Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Resverlogix Corp

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

              Contact the Supplier

              Lead Product(s): Apabetalone,Atorvastatin

              Therapeutic Area: Endocrinology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 30, 2020

              Details:

              Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.

              Resverlogix Corp

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Resverlogix Receives FDA Breakthrough Therapy for Apabetalone

              Contact the Supplier

              Lead Product(s): Apabetalone

              Therapeutic Area: Endocrinology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 03, 2020

              Details:

              FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.

              PharmaCompass__DigitalAd